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To the Editor: 
 
We read with interest Joshita and colleagues’ letter regarding our original article [1]. 
In taking the time to present their important Japanese data [2], the authors provide 
further independent validation of AST/platelet ratio (APRI) in risk stratification of 
patients with primary biliary cirrhosis (PBC). As the authors surmise, whilst the 
demography of our cohorts was varied it was not representative of all populations 
globally, and the robustness of any observation – even if simple and low cost as in 
this case – is in validation more so than discovery.  
 
PBC is not a benign, homogeneous autoimmune liver disease; and although present 
disease nomenclature needs improvement, the current sole therapy - ursodeoxycholic 
acid (UDCA) - still leaves a substantial cohort of individuals at risk from life-
threatening progressive disease and impaired quality of life. Risk stratification is 
therefore of value to identify individuals with PBC who will benefit from new 
treatment and as illustrated herein, APRI at baseline or reapplied 1-year following 
therapy (APRI-r1) represents an additive tool in identifying those patients at risk of 
adverse clinical outcome with high accuracy. Joshita et al. also report good 
correlation between APRI and disease stage; [2] however, it is apparent in both 
studies that a significant proportion of patients have an APRI >0.54 despite 
histological evidence of early stage (I-II) disease. Moreover, in our study we were 
able to show that in those without objective evidence of cirrhosis APRI retains 
independent predictive value thus supporting APRI/APRI-r1 as a prognostic, 
clinically meaningful utility beyond application as a surrogate for liver fibrosis.   
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The ability to reliably predict outcome in patients with PBC is beneficial for patient 
counselling, timing of diagnostic procedures and therapeutic intervention. In this 
regard, prospective evaluation of APRI-r1 in terms of additive value to existing 
UDCA response criteria is of clear importance; particularly given the potential use of 
surrogate endpoints in development of new treatments in PBC [3–5]. Our 
observations alongside those of Joshita et al., further substantiate the role stratification 
could play not just in clinical practice but also in clinical trial design. Hence future 
therapeutic trials in PBC should consciously consider inclusion criteria beyond classic 
response criteria, and such stratifiers may include additional tools such as liver 
elastography and APRI-r1. Finally as is evident by our studies, in the pursuit of 
optimal management for a rare disease such as PBC, methodologically robust, 
internationally representative, numerically well-powered cohorts are essential in order 
to allow investigators to make clear replicated observations about disease nature, 
course and intervention. 
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